GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » Book Value per Share

Kala Bio (Kala Bio) Book Value per Share : $2.72 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Book Value per Share?

Kala Bio's book value per share for the quarter that ended in Dec. 2023 was $2.72.

During the past 12 months, Kala Bio's average Book Value Per Share Growth Rate was -75.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -68.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -52.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Kala Bio was -22.60% per year. The lowest was -68.20% per year. And the median was -45.90% per year.

Kala Bio's current price is $6.73. Its book value per share for the quarter that ended in Dec. 2023 was $2.72. Hence, today's PB Ratio of Kala Bio is 2.48.

During the past 9 years, the highest P/B Ratio of Kala Bio was 8.97. The lowest was 0.79. And the median was 2.79.


Kala Bio Book Value per Share Historical Data

The historical data trend for Kala Bio's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Book Value per Share Chart

Kala Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only 41.14 84.86 12.83 11.12 2.72

Kala Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.12 10.16 6.89 4.17 2.72

Competitive Comparison of Kala Bio's Book Value per Share

For the Biotechnology subindustry, Kala Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kala Bio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kala Bio's PB Ratio falls into.



Kala Bio Book Value per Share Calculation

Kala Bio's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7.50-0.00)/2.76
=2.72

Kala Bio's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7.50-0.00)/2.76
=2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Kala Bio  (NAS:KALA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Kala Bio Book Value per Share Related Terms

Thank you for viewing the detailed overview of Kala Bio's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kala Bio (Kala Bio) Business Description

Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Executives
Todd Bazemore officer: Chief Operating Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell officer: Chief Medical Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg officer: See Remarks 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi officer: CHIEF BUSINESS OFFICER C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki director, officer: Chief Executive Officer 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth officer: Chief Financial Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid director C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen officer: Chief Scientific Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg director 100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116